Vetiqure would like to thank its customers, distributors and partners for a successful first half of the year!
After an intensive first six months, we proclaim that we have made great clinical and commercial progress in the establishment of our unique Tumour Specific Electroporation technology (TSE) on the veterinary market in Europe, Australia as well as in the USA.Following installations of TSE, after thorough evaluations, at leading universities in the UK, Turkey, and Australia, we have now also established customer relations with some of USA's and Scandinavia's largest players in veterinary healthcare. This is not only a seal of quality, but of course will create opportunities to build long-term